|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0008976,
umls-concept:C0027627,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0087111,
umls-concept:C0205390,
umls-concept:C0257685,
umls-concept:C0280100,
umls-concept:C0443252,
umls-concept:C0521324,
umls-concept:C0684249
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2004-6-15
|
|
pubmed:abstractText |
The authors previously reported the efficacy of a dose of 4 mg of zoledronic acid in reducing skeletal complications in patients with bone metastases secondary to lung carcinoma and other solid tumors (except carcinomas of the breast and prostate). In the current study, they update these results and report the long-term efficacy and safety of 21 months of treatment with zoledronic acid in a randomized, placebo-controlled trial.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:De SouzaPaulP,
pubmed-author:GordonDavidD,
pubmed-author:HirshVeraV,
pubmed-author:KrzakowskiMaciejM,
pubmed-author:PawlickiMarekM,
pubmed-author:ReitsmaDirkD,
pubmed-author:RosenLee SLS,
pubmed-author:SeamanJohnJ,
pubmed-author:TchekmedyianN SimonNS,
pubmed-author:UrbanowitzGladysG,
pubmed-author:YanagiharaRonaldR,
pubmed-author:ZhengMingM
|
|
pubmed:copyrightInfo |
Copyright 2004 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
100
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2613-21
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
Developmental Therapeutics, Cancer Institute Medical Group, Los Angeles, California 90025, USA. lrosen@targenix.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
